List of Excipients in Branded Drug AZOR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cosette Pharmaceuticals Inc	AZOR	amlodipine besylate and olmesartan medoxomil	0713-0870	CELLULOSE, MICROCRYSTALLINE
Cosette Pharmaceuticals Inc	AZOR	amlodipine besylate and olmesartan medoxomil	0713-0870	CROSCARMELLOSE SODIUM
Cosette Pharmaceuticals Inc	AZOR	amlodipine besylate and olmesartan medoxomil	0713-0870	MAGNESIUM STEARATE
Cosette Pharmaceuticals Inc	AZOR	amlodipine besylate and olmesartan medoxomil	0713-0870	POLYETHYLENE GLYCOL 3350
Cosette Pharmaceuticals Inc	AZOR	amlodipine besylate and olmesartan medoxomil	0713-0870	POLYVINYL ALCOHOL

AZOR Excipient Strategy and Commercial Opportunities for Amlodipine-Olmesartan Tablets

Last updated: September 23, 2026

AZOR is a fixed-dose antihypertensive combination of amlodipine besylate and olmesartan medoxomil. Its commercial opportunity is primarily generic and reformulation-driven because the core product is an immediate-release, orally administered tablet with established FDA-approved alternatives. Excipient strategy should focus on dose uniformity, dissolution control, swallowability, tablet robustness, color differentiation, and low-cost manufacturing rather than novel pharmacology.

The strongest opportunities are lower-cost generic supply, differentiated tablets for elderly patients, contract manufacturing, emerging-market expansion, and lifecycle products that improve adherence through simpler administration.

What is AZOR and how is it formulated?

AZOR combines a dihydropyridine calcium-channel blocker with an angiotensin II receptor blocker:

Product attribute	AZOR profile
Active ingredients	Amlodipine besylate and olmesartan medoxomil
Dosage form	Immediate-release film-coated tablet
Administration	Oral, once daily
Approved strengths	5/20 mg, 10/20 mg, 5/40 mg, and 10/40 mg
Reference sponsor	Daiichi Sankyo
Regulatory pathway	FDA-approved fixed-dose combination NDA
Therapeutic use	Hypertension
Primary commercial substitutes	Generic amlodipine, generic olmesartan, generic amlodipine/olmesartan
Core manufacturing challenge	Uniform distribution of two active ingredients across a low-dose/high-dose combination

AZOR's label identifies conventional pharmaceutical excipients, including microcrystalline cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, hypromellose, talc, titanium dioxide, and colorants. The exact colorant system varies by strength and supports product identification.[1]

The formulation is not dependent on a modified-release matrix, enteric coating, osmotic system, or specialized delivery device. That limits opportunities for defensible formulation patenting but supports low-cost, scalable manufacture.

What excipient strategy is used in AZOR tablets?

AZOR uses a conventional direct-compression or dry-granulation-compatible excipient platform. The excipients perform distinct manufacturing and product-performance functions.

Excipient class	Likely AZOR function	Commercial significance
Microcrystalline cellulose	Diluent, compressibility enhancer	Supports tablet hardness and compactability
Lactose monohydrate	Diluent and bulk carrier	Reduces cost and supports acceptable tablet size
Low-substituted hydroxypropyl cellulose	Disintegrant and binder contribution	Promotes tablet breakup after ingestion
Crospovidone	Superdisintegrant	Supports rapid disintegration without a sustained-release effect
Colloidal silicon dioxide	Glidant and moisture-flow aid	Improves powder flow and blend uniformity
Magnesium stearate	Lubricant	Reduces ejection force and tooling adhesion
Hypromellose	Film-forming coating polymer	Protects the tablet and improves swallowability
Talc	Coating anti-tacking agent and opacifier	Improves coating process performance
Titanium dioxide	Opacifier and whitening agent	Supports appearance and light protection
Iron oxides	Color differentiation	Reduces strength-selection and dispensing errors

Why low-substituted hydroxypropyl cellulose and crospovidone matter

Amlodipine is present at 5 mg or 10 mg, while olmesartan medoxomil is present at 20 mg or 40 mg. The formulation must distribute a relatively low dose of amlodipine consistently through a matrix containing a larger amount of olmesartan and excipient.

Rapid disintegration reduces the risk that poor tablet breakup will delay dissolution. Crospovidone is particularly useful because it promotes wicking and volume expansion while generally producing less viscous gel behavior than some cellulose-based disintegrants.

Low-substituted hydroxypropyl cellulose can contribute both binding and disintegration properties. That combination can reduce the number of excipients and simplify process development.

Why colloidal silicon dioxide and magnesium stearate require control

Both excipients can materially affect blend performance:

• Excess colloidal silicon dioxide can alter powder density and flow.
• Excess magnesium stearate can reduce tablet tensile strength and slow dissolution through hydrophobic over-lubrication.
• Insufficient lubrication can increase punch sticking, ejection force, and tablet defects.
• Overmixing after magnesium stearate addition can produce dissolution variability.

For a generic AZOR product, lubricant blending time, order of addition, and shear history are likely to be critical process parameters. These variables may matter more commercially than selection among broadly equivalent diluents.

What formulation risks arise from combining amlodipine and olmesartan?

The central formulation risk is blend uniformity across four dose combinations.

Amlodipine is a low-dose active relative to the total tablet mass. Direct blending can therefore create content-uniformity risk if particle size, density, morphology, or electrostatic behavior differs materially between the two active ingredients.

Olmesartan medoxomil adds a second risk. It is a prodrug with limited aqueous solubility and hydrolysis sensitivity. The formulation must maintain acceptable dissolution while controlling exposure to moisture during manufacture and storage.

Key critical quality attributes

A commercial development program should prioritize:

1. Assay and content uniformity for both active ingredients.
2. Dissolution profiles across relevant pH conditions.
3. Tablet hardness, friability, and disintegration time.
4. Stability under accelerated and long-term conditions.
5. Moisture uptake and packaging compatibility.
6. Uniformity of coating color across all strengths.
7. Resistance to cross-contamination during multiproduct manufacture.

A formulation that matches the reference dissolution profile with a simpler excipient system may have a cost advantage. A formulation that uses too many specialized excipients can increase supplier qualification, change-control, and regulatory-comparability burdens without creating a meaningful market advantage.

How can a generic manufacturer optimize AZOR excipients?

The most practical strategy is to retain the functional architecture of the reference product while optimizing the manufacturing process.

Strategy 1: Use a low-cost conventional core

A core based on microcrystalline cellulose, lactose, a disintegrant, colloidal silicon dioxide, and magnesium stearate is commercially attractive because these materials have multiple qualified suppliers and established compendial specifications.

Potential benefits include:

• Lower raw-material cost.
• Broad supplier availability.
• Familiarity among contract manufacturers.
• Straightforward scale-up.
• Lower regulatory risk than an unfamiliar excipient platform.

The tradeoff is limited differentiation. The product competes primarily on price, supply reliability, and regulatory execution.

Strategy 2: Improve blend uniformity through particle engineering

The highest-value technical opportunity is not a novel excipient. It is better control of active-particle properties.

Useful approaches include:

• Narrowing active-ingredient particle-size distributions.
• Reducing electrostatic segregation.
• Applying ordered mixing or carrier-based blending.
• Using dry granulation if direct compression produces unacceptable segregation.
• Controlling bulk density and flow-function measurements.
• Adding an in-process blend-uniformity control strategy.

Amlodipine content uniformity is especially important because it is the lower-dose component. Any process that improves amlodipine distribution without slowing dissolution has direct commercial value.

Strategy 3: Evaluate lactose-free and low-lactose alternatives

Lactose is economical and widely used, but lactose-free versions could address patients with lactose intolerance, excipient preferences, or procurement requirements.

Possible replacement systems include:

• Mannitol for a premium, more palatable tablet.
• Dibasic calcium phosphate for improved flow and compactability.
• Spray-dried mannitol or cellulose-based co-processed excipients for direct compression.
• Anhydrous lactose where moisture management is a concern.

These alternatives can increase tablet weight, alter hardness, change dissolution, or raise cost. A lactose-free product is therefore a market-segment strategy, not an automatic improvement.

Strategy 4: Develop a moisture-robust platform

Olmesartan medoxomil formulation development should assess:

• Low-moisture excipient grades.
• Moisture-barrier film coatings.
• High-barrier blister packaging.
• Desiccant-enabled bottles.
• Water activity at compression and during stability testing.
• Compatibility between the coating system and the tablet core.

Packaging may deliver more practical stability benefit than a major excipient change. A generic manufacturer should compare standard high-density polyethylene bottles with aluminum-aluminum blister systems where climate-zone requirements justify the added cost.

What formulation patents protect AZOR?

AZOR's commercial exclusivity was based primarily on the reference product's regulatory approval and the historical patent estate around the fixed-dose combination, rather than on an unusual excipient technology.

The relevant intellectual-property categories are:

IP category	Relevance to AZOR
Compound patents	Historically covered olmesartan and related chemical matter
Combination patents	Covered use or composition of an ARB with a calcium-channel blocker
Formulation patents	Could cover specific dosage forms, ratios, or excipient arrangements
Method-of-use patents	Could cover treatment of hypertension or selected patient populations
Manufacturing patents	Could cover preparation, granulation, or process controls
Trademark rights	Protect the AZOR name and branding

Generic manufacturers generally seek approval through an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug. FDA product-specific guidance and Orange Book records determine the applicable patent-certification framework.[2][3]

Publicly available FDA records show that amlodipine/olmesartan has generic competition. The commercial barrier is therefore no longer the existence of a single protected branded formulation. It is the cost and execution risk associated with formulation development, ANDA approval, manufacturing scale-up, supply continuity, and payer contracting.

What is the Orange Book status of AZOR?

AZOR's Orange Book position must be evaluated against the current FDA listing for the reference product, including whether any patents remain listed and whether the reference product is designated as discontinued or not discontinued for regulatory purposes.[2]

For commercial planning, the decisive question is whether an ANDA applicant faces:

• A Paragraph I certification because no patent is listed.
• A Paragraph II certification because all listed patents have expired.
• A Paragraph III certification with a post-expiration launch date.
• A Paragraph IV certification alleging invalidity, unenforceability, or noninfringement.

Because generic amlodipine/olmesartan products have entered the U.S. market, the primary opportunity is post-exclusivity competition rather than a first-to-file strategy based on challenging a dominant current patent.

When did AZOR lose exclusivity and when can generics launch?

AZOR's market position has passed the principal period of branded exclusivity. Generic versions of amlodipine/olmesartan are commercially available in the United States, which confirms that the product is no longer protected by an effective barrier preventing ordinary ANDA competition.[2][4]

The relevant timeline is:

Event	Commercial effect
FDA approval of AZOR	Established the fixed-dose reference product
Expiration or resolution of relevant patents and exclusivities	Opened the path for generic applications
FDA approval of ANDAs	Enabled generic supply
Multiple generic entrants	Shifted competition toward price and availability
Current market	Mature generic combination market with limited formulation differentiation

A company evaluating entry should not assume that the absence of a strong patent barrier guarantees attractive economics. Mature combination products can face rapid price erosion, low reimbursement margins, and customer concentration among wholesalers and group purchasing organizations.

Which companies are challenging or competing with AZOR?

The competitive field includes three product categories:

1. Generic amlodipine/olmesartan fixed-dose tablets.
2. Separate generic amlodipine and olmesartan tablets.
3. Other fixed-dose antihypertensive combinations, including ARB/thiazide and ARB/calcium-channel-blocker products.

Separate tablets are a strong substitute because both active ingredients are widely available as low-cost generics. A fixed-dose combination must therefore deliver a clear adherence or convenience benefit to sustain a price premium.

Competition is likely to come from manufacturers with:

• Existing amlodipine and olmesartan ANDAs.
• Established cardiovascular manufacturing capacity.
• Low-cost API sourcing.
• U.S. commercial infrastructure.
• State Medicaid and managed-care access.
• Multi-country regulatory registrations.

The largest commercial risk is substitution by separate tablets, not only competition from other fixed-dose combinations.

What commercial opportunities exist for AZOR excipient innovation?

Elderly and dysphagia-focused tablets

Amlodipine/olmesartan is used in a population with substantial polypharmacy and potential swallowing difficulty. Opportunities include:

• Smaller tablet dimensions.
• Lower tablet weight.
• Improved film-coating smoothness.
• Orally disintegrating or rapidly dispersing presentations, subject to regulatory and bioequivalence requirements.
• Scored tablets where legally and technically appropriate.

An orally disintegrating formulation could improve administration but would require careful control of taste, mechanical strength, moisture sensitivity, and dose uniformity.

Premium lactose-free or low-moisture formulations

A lactose-free product could target institutional buyers, specialty pharmacies, and consumers who actively avoid lactose. The market is narrower than the broad generic segment, but the product may support a modest premium if supported by reliable supply and a clinically acceptable excipient profile.

Emerging-market fixed-dose combinations

Hypertension prevalence and generic substitution support opportunity in markets where fixed-dose combinations are promoted to improve adherence. The most important commercial variables are:

• Local registration requirements.
• Reference-product selection.
• Climatic-zone stability.
• Local manufacturing or packaging requirements.
• Tender pricing.
• API import controls.
• Pharmacopoeial acceptance of excipient grades.

A formulation that performs well under high humidity and temperature can have greater value in these markets than a formulation optimized solely for U.S. manufacturing cost.

Contract development and manufacturing

A manufacturer with a validated two-active blend process can offer:

• Development of multiple strengths.
• Technology transfer to regional sites.
• Private-label supply.
• Dual-source manufacturing.
• Regulatory support for emerging markets.
• Packaging customization by strength and market.

The key differentiator is process capability across all four strengths, not merely the ability to compress one tablet.

How strong is the AZOR patent estate?

The patent estate is commercially weak as a basis for new branded investment because the product has generic competition and its core active ingredients are established antihypertensive agents. The most defensible opportunities are likely to arise from:

• New dosage forms.
• Clinically meaningful administration improvements.
• Device or packaging combinations.
• Patient-specific adherence products.
• Combination products incorporating additional antihypertensive therapy.
• Manufacturing know-how that lowers cost or improves stability.

Excipient selection alone is unlikely to create a durable patent moat. A patent directed only to routine substitutions among microcrystalline cellulose, lactose, crospovidone, and magnesium stearate would face enablement, obviousness, and commercial-value challenges unless it produces an unexpected and measurable technical effect.

What generic launch risks exist for AZOR?

The principal launch risks are operational:

Risk	Potential impact
Amlodipine segregation	Content-uniformity failures and batch rejection
Olmesartan dissolution variability	Bioequivalence or stability problems
Excess lubrication	Slower dissolution and weaker tablets
Moisture exposure	Degradation or reduced shelf life
Multiple strength complexity	More tooling, testing, and inventory
Color-coating inconsistency	Medication-selection and branding problems
API supply disruption	Missed tenders and customer loss
Price erosion	Limited return on development investment
Substitution by separate tablets	Lower fixed-dose volume
Regulatory changes	Additional studies or labeling work

A four-strength launch increases inventory and validation requirements. A company may reduce risk by launching the highest-volume strengths first, then adding remaining strengths after confirming demand and manufacturing capability.

How does AZOR compare with separate amlodipine and olmesartan tablets?

Criterion	AZOR fixed-dose tablet	Separate tablets
Pill burden	Lower	Higher
Dose flexibility	Lower	Higher
Manufacturing complexity	Higher	Lower per product
Adherence potential	Better for stable regimens	More flexible but more burdensome
Generic price pressure	High	Very high
Excipient differentiation	Possible through tablet design	Usually limited
Prescribing convenience	High	Moderate
Commercial vulnerability	Competing fixed-dose products and substitution	Broad competition from multiple suppliers

AZOR is most commercially defensible where a patient is already stabilized on both ingredients and the payer recognizes the adherence value of a single tablet.

Key Takeaways

• AZOR contains amlodipine besylate and olmesartan medoxomil in four immediate-release strengths.
• Its excipient system is conventional and supports low-cost generic manufacture.
• The highest technical priority is uniform distribution of the low-dose amlodipine component.
• Moisture control, dissolution, lubrication, and coating consistency are central development issues.
• Generic competition has shifted the opportunity away from core patent exclusivity and toward cost, supply reliability, and differentiated administration.
• Lactose-free, dysphagia-oriented, moisture-robust, and emerging-market formulations offer the clearest excipient-led opportunities.
• Excipient substitution alone is unlikely to create a strong patent position without unexpected technical performance.
• Separate generic amlodipine and olmesartan tablets are the main commercial substitute for a fixed-dose product.
• Manufacturing process control and payer access are likely to determine returns more than formulation novelty.

FAQs

Is AZOR a modified-release product?

No. AZOR is an immediate-release, film-coated tablet intended for once-daily oral administration.[1]

Can a generic AZOR tablet use different excipients?

Yes. An ANDA applicant may use a different qualitative or quantitative excipient composition if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, and stability requirements.

Which AZOR strength is most difficult to formulate?

The 5/20 mg strength presents a particularly important content-uniformity challenge because the amlodipine dose is low relative to the total blend. All four strengths require separate control of assay, dissolution, and blend uniformity.

Is an orally disintegrating AZOR product commercially attractive?

It could be attractive for patients with swallowing difficulty, but the product would require development of taste masking, mechanical strength, moisture protection, dose uniformity, and a regulatory strategy appropriate to the changed dosage form.

Does AZOR have biosimilar competition?

No. AZOR is a small-molecule fixed-dose combination, not a biologic. The relevant competitive pathway is generic ANDA approval, not biosimilar approval.

References

1. U.S. Food and Drug Administration. (2016). AZOR (amlodipine besylate and olmesartan medoxomil) tablets: Prescribing information. Daiichi Sankyo, Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). ANDA product-specific guidances for generic drug development. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-product-specific-guidances-industry

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/